Rafael Fonseca/X
Dec 9, 2024, 20:13
Rafael Fonseca: Discontinuation of lenalidomide maintenance based on MRD
Rafael Fonseca, Hematologist at Mayo Clinic, shared a post on X:
“Discontinuation of lenalidomide maintenance based on MRD status.
Most treated with triplets. A bit enriched for lower risk cases (by definition by being sustained MRD-).”
Dr. Rafael Fonseca, M.D., is a hematologist at Mayo Clinic, specializing in multiple myeloma and related conditions. Dr. Fonseca’s expertise extends to diagnosing and treating plasma cell disorders, leading clinical trials that have advanced myeloma treatment. He has led research on genetic markers in myeloma.
Dr. Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award and the International Waldenström Macroglobulinemia Research Award.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 10, 2024, 16:55
Dec 10, 2024, 16:40
Dec 10, 2024, 16:34
Dec 10, 2024, 16:32
Dec 10, 2024, 16:19
Dec 10, 2024, 16:07
Dec 10, 2024, 16:04
Dec 10, 2024, 14:47
Dec 10, 2024, 14:37